Administration of Palivizumab: A Medical Provider's Perspective
- 1 November 2003
- journal article
- other
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 42 (9) , 821-826
- https://doi.org/10.1177/000992280304200908
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomesThe Pediatric Infectious Disease Journal, 2002
- Factors Predicting Compliance with Palivizumab in High-Risk InfantsAmerican Journal of Perinatology, 2001
- Development of local guidelines for prevention of respiratory syncytial viral infectionsThe Pediatric Infectious Disease Journal, 1999
- Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis Among Preterm InfantsPublished by American Academy of Pediatrics (AAP) ,1999
- Prophylaxis against respiratory syncytial virus in premature infantsThe Lancet, 1999
- Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: Potential for savingsPublished by Elsevier ,1999
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998